2 terminated, 1 enrolling by invitation, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Enrolling by invitation 1, Withdrawn 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Neutropenia, severe chronic: new trials by email Literature Review of Neutropenia, severe chronic trials Research Report on Neutropenia, severe chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Shwachman-Diamond Syndrome, SDS | Recruiting | Shwachman-Diamond Syndrome Alliance Inc | 8000 | 2024-02-07 | 2025-05-31 | |
| ANF-Rho in the Treatment of Chronic Neutropenia ANF-Rho - Neutropenia, Severe Chronic | Phase 1 / Phase 2 | Withdrawn | Prolong Pharmaceuticals | 2015-10-01 | 2019-03-06 | |
| Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases CD3/CD19 negative allogeneic hematopoietic stem cells - Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 16 | 2013-06-20 | 2025-12-15 |
| Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia Filgrastim - Severe Chronic Neutropenia | Phase 4 | Terminated | Sandoz | 6 | 2011-07-01 | 2016-03-28 |
| Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Ezatiostat Hydrochloride - Severe Chronic Neutropenia | Phase 2 | Terminated | Telik | 9 | 2009-04-01 | 2013-11-25 |
| International Registry for Severe Chronic Neutropenia Neutropenia | Unknown | National Center for Research Resources (NCRR) | 1000 | 1994-06-01 | 2020-10-22 |
Neutropenia (2) · Common Variable Immunodeficiency (1) · Congenital Bone Marrow Failure Syndromes (1) · Exocrine Pancreatic Insufficiency (1) · Granulomatous Disease, Chronic (1) · Hematologic Diseases (1) · Immunologic Deficiency Syndromes (1) · Job Syndrome (1) · Lymphoma, Follicular (1) · Myelodysplastic Syndromes (1) · Neoplastic Syndromes, Hereditary (1) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (1) · Pancytopenia (1) · Primary Immunodeficiency Diseases (1)
Cytopenia (4) · Hemic and Lymphatic Diseases (4) · Hematologic Diseases (3) · Leukocyte Disorders (3) · Leukopenia (3) · Agranulocytosis (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Disease Attributes (2) · Genetic Diseases, Inborn (2) · Immune System Diseases (2) · Infant, Newborn, Diseases (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Filgrastim (1) · gamma-Glu-S-BzCys-PhGly diethyl ester (1) · pegfilgrastim (1) · pegylated granulocyte colony-stimulating factor (1)
National Center for Research Resources (NCRR) (1) · Paul Szabolcs (1) · Prolong Pharmaceuticals (1) · Sandoz (1) · Shwachman-Diamond Syndrome Alliance Inc (1) · Telik (1)
United States (4) · Germany (2) · Australia (1) · Canada (1) · Sweden (1) · United Kingdom (1)
David Chandler Dale (1) · Gail Brown, MD (1) · Hemant Misra, PhD (1) · Paul Szabolcs, MD (1) · Roumen Nakov, MD, PhD (1)